Short answer
Agilent Technologies (A) filed its fiscal 2025 10-K annual report with the SEC on Dec 22, 2025. It reported revenue of $6.9B (+6.7% year over year) and net income of $1.3B.
- Top risk flagged: Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025
FY2025 key financial metrics · XBRL
- Revenue
- $6.9B
- +6.7% YoY
- Net income
- $1.3B
- +1.1% YoY
- Operating margin
- 21.3%
- −1.6 pp YoY
- EPS (diluted)
- $4.57
- +3.2% YoY
- ROE
- 19.3%
- −2.5 pp YoY
- Operating cash flow
- $1.6B
- −11.0% YoY
Source: XBRL data from the Agilent Technologies (A) FY2025 10-K on SEC EDGAR. USD.
Agilent Technologies FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Provider of scientific instruments and analytical solutions for laboratories and research
- No new products, services, or business segments introduced or emphasized in this year's filing
- Continued focus on equity compensation plans, including 2018 Stock Plan with 38.8 million shares available for future issuance
- Notable metric: 2,954,318 securities outstanding under equity compensation plans with weighted-average exercise price $134
- Most unusual detail: Annual increase mechanism in Employee Stock Purchase Plan allows up to 1% of outstanding shares for future issuance
Management Discussion & Analysis
- Revenue and profitability figures not disclosed in provided MD&A text
- No cash flow, buybacks, dividends, or capex details mentioned
- Forward-looking statements highlight growth opportunities, investments, market demand, and macroeconomic risks without specific guidance or figures
Risk Factors
- Regulatory risk from Inflation Reduction Act 2022, 1% nondeductible excise tax on stock repurchases payable, $3 million recorded in fiscal 2025
- Geopolitical risk from U.S. tariff changes in H2 2025 increasing cost of revenue; mitigation expected in fiscal 2026 through supply chain and pricing actions
- Operational risk in inventory valuation: potential write-downs if actual market conditions worsen beyond management's estimates on excess and obsolete inventory
- Competitive risk from capital spending declines in pharmaceutical market affecting Life Sciences and Diagnostics segment revenue growth, down 11% in 2024 vs 2023
- Financial risk from goodwill and intangible asset impairment assessment, relying on significant estimates including revenue growth and discount rates, with no impairment recognized in 2025
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.